Related Experiment Video

Updated: Dec 17, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

Medical Management of COVID-19: Evidence and Experience

Subhasish Bose1, Sreedhar Adapa2, Narothama Reddy Aeddula3

  • 1Division of Nephrology, Department of Internal Medicine, University of Virginia, Lynchburg, VA 24501-1167, USA.

Journal of Clinical Medicine Research
|June 27, 2020
PubMed

Insights

Currently, no definitive cure exists for Coronavirus disease 2019 (COVID-19). This review summarizes experimental and supportive therapies for COVID-19 patients, addressing confusion among healthcare professionals regarding treatment options.

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has resulted in millions of global infections and deaths.
  • Despite ongoing research and emergency use authorizations (e.g., remdesivir), a conclusively proven curative therapy for COVID-19 remains elusive.
  • Mixed results from drug trials and observational studies have led to confusion among healthcare professionals (HCPs) regarding optimal treatment strategies.

Purpose of the Study:

  • To collate and summarize current treatment strategies for COVID-19 patients.
  • To discuss pharmacologic and other therapies for COVID-19, including experimental and supportive care options.
  • To provide clarity for healthcare professionals managing COVID-19 patients with varying illness severity.

Main Methods:

  • This article is a review of existing literature and clinical trial data.
  • It synthesizes information on pharmacological and non-pharmacological interventions for COVID-19.
  • The review focuses on therapies for patients with mild to severe illness.

Main Results:

  • The review highlights the lack of a definitive cure for COVID-19 as of June 2020.
  • It discusses remdesivir's emergency use authorization (EUA) but acknowledges mixed results from other drug trials.
  • The article emphasizes the need for continued research into effective COVID-19 treatments.

Conclusions:

  • Effective and universally accepted treatment protocols for COVID-19 are still under development.
  • A comprehensive understanding of available experimental and supportive therapies is crucial for managing COVID-19 patients.
  • Further clinical trials are necessary to establish definitive therapeutic guidelines for COVID-19.

Keywords:
Coronavirus disease 2019ESKDHIVMedical managementPharmacological treatmentSARS-CoV-2Transplant

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
109
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
625
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
655
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
4.9K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
359